PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study
Latest Information Update: 20 Jun 2025
At a glance
- Drugs Evolocumab (Primary) ; Rosuvastatin
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms ETACS; SHAWN
Most Recent Events
- 13 Jun 2025 Planned End Date changed from 30 Jan 2029 to 30 Sep 2030.
- 13 Jun 2025 Planned primary completion date changed from 30 Jan 2026 to 30 Sep 2026.
- 14 May 2023 Status changed from not yet recruiting to recruiting.